fbpx

BONESUPPORT Launches New Web Site

BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced the launch of a new corporate web site. The new web site aims to update the BONESUPPORT brand while providing increased educational and clinical CERAMENTT content to an expanding audience.

“Our business has evolved since the company's inception in 1999,” said Lloyd Diamond, CEO of BONESUPPORT. “Moving from a research and development business to a fully commercial and multi channeled business requires us to effectively communicate with a broader customer base. I am pleased that our new web site allows visitors to access information based on their interests and application needs.”

CERAMENTT is an injectable, synthetic bone substitute that mimics the properties of cancellous bone, allows for controlled resorption to support future bone ingrowth and is injectable under local anesthesia for minimally invasive surgery. CERAMENTT's unique biologic properties deliver a consistent, pre-packed and ready-to-use formulation to facilitate optimal delivery.

Mr. Diamond added, “With orthopedic trauma and bone infection rates dramatically increasing, it is very important to broadly and effectively educate patients and surgeons that there is a technology available that can deliver a less painful, minimally invasive and more effective treatment. This site truly reflects our strong commitment to innovation, education and improved clinical outcomes.”

For more information about BONESUPPORT and CERAMENTT, visit their new site at www.bonesupport.com

About BONESUPPORT:
BONESUPPORT is an emerging leader of injectable bone substitutes for orthopedic trauma focusing on bone infection, instrument augmentation related to orthopedic surgery and spinal applications. CERAMENTT is a fully developed product platform that is commercially available in the U.S. and Europe and is revolutionizing the treatment of fragility and other fractures caused by disease and trauma. Scientific research of CERAMENTT spans more than eleven years and over forty-five pre-clinical, clinical and animal studies have been conducted. More than 4,000 patients have been treated with CERAMENTT. The company was founded in 1999 and is based in Lund, Sweden with subsidiary locations in the US and Germany. To learn more about BONESUPPORT please visit www.bonesupport.com

Press Inquiries:
Fredrik Groth
CFO

Phone: +46 46 286 53 60
Fredrik.Groth@bonesupport.com

Nyheder

Syv forskningsinstitutioner får 20 mio. kr. til corona-forskning
1. april 2020
Sådan håndterer vi ændring af forskningsprojekter under corona-pandemien
31. marts 2020
Første Corona-bevilling fra Lundbeckfonden til forsøg med et kendt lægemiddel
26. marts 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge